really amazing explaination about the phase1 result from the MD tweet! I think people should easily understand such an excellent result.
Epidyolex make around $600m US dollars sales per year. but there are some disadvantage about epidyolex such as very high cost, it is oil which make people very hard to consume and it is not that stable.
RX5 so far has showed the drug can overcome all the epidyolex disadvantages. I am really happy about the result. I think EMD will have great future.
RX5 is just one of them. also RX7 and other drugs development program.
the market hasn't realize the huge potential of EMD.
really excited about EMD!
EMD Price at posting:
27.5¢ Sentiment: Buy Disclosure: Held
